It is worth noting that, the dosing levels of a MDM2 inhibitor required for p53 activation in the cellular compartment of the TME and reversal of immunosuppression are well below the dose levels for exerting direct tumoricidal activity against tumor cells [39]. The gene discussed is TP53; the disease is neoplasm.